Robbins Umeda LLP Announces an Investigation of Accretive Health, Inc.

Date : 04/30/2012 @ 1:47PM
Source : Business Wire
Stock : R1 Rcm Inc. (RCM)
Quote : 7.77  0.03 (0.39%) @ 8:00PM
R1 RCM Inc. share price Chart

Robbins Umeda LLP Announces an Investigation of Accretive Health, Inc.

Historical Stock Chart

5 Years : From Mar 2013 to Mar 2018

Click Here for more R1 RCM Inc. Charts.

Shareholder rights firm Robbins Umeda LLP is investigating possible breaches of fiduciary duty and other violations of the law by certain officers and directors at Accretive Health, Inc. (NYSE: AH). Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Gregory E. Del Gaizo at (800) 350-6003,, or via the shareholder information form on the firm's website.

Robbins Umeda LLP is investigating whether officers and directors at Accretive Health breached their fiduciary duties to shareholders by causing the company to issue improper public statements regarding Accretive Health's new Quality and Total Cost of Care service initiative and failing to maintain adequate internal oversight. In particular, Robbins Umeda is investigating whether the company's fiduciaries failed to disclose that it was violating health privacy laws, state debt collection laws, and state consumer protection laws. On March 29, 2012, Accretive Health announced that, in response to a lawsuit filed by Minnesota's Attorney General, the company had agreed to no longer collect debts on behalf of Fairview Health Services. On this news, Accretive Health's stock dropped $4.46 per share to close at $19.60 on March 29, 2012, a one-day decline of nearly 19%.

Subsequently, on April 24, 2012, the Minnesota Attorney General released a report which highlighted allegedly aggressive and improper practices used by Accretive Health, including demanding payment from patients seeking care in emergency rooms, cancer wards, and delivery rooms. As a result of this news, Accretive Health's stock fell another $7.63 per share to close at $10.86 per share on April 25, 2012, a one-day decline of 41%. Since these facts have emerged, Accretive Health has increasingly become the focus of costly public and legal scrutiny that continues to undermine the company's prospects and value for shareholders.

Robbins Umeda LLP highlights that Accretive Health shareholders have the option to file a shareholder derivative action to hold those officers and directors accountable for damaging the company. Remedies commonly sought in derivative actions include corporate governance reforms designed to prevent future misconduct, removal of officers or directors whose misconduct injured the corporation, and monetary payments in the form of damages and disgorgement of ill-gotten gains.

Robbins Umeda LLP is a nationally recognized leader in securities litigation and shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. For more information, please go to

Press release link:

Attorney Advertising. Past results do not guarantee a similar outcome.

Latest RCM Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V:us D:20180318 21:14:39